END-TO-END CELL THERAPY AUTOMATION

The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.

Saved in:
Bibliographic Details
Main Authors MCAFEE, Erika, SIEHOFF, Ann, ABRAHAM, Eytan, SHI, Yaling, O'CONNOR, Joseph, PURPURA, Kelly, SMITH, Timothy, GLEISSNER, Timo, TRAINOR, Nuala, BANDAPALLE, Samatha
Format Patent
LanguageEnglish
Published 15.02.2024
Subjects
APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
Bibliography:Application Number: US202318496573